Late Events Occurring After 5 Years in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group

Sara Kreimer; Wei Xue; Amira Qumseya; Timothy B. Lautz; Archana Shenoy; Susan Hiniker; Dana Casey; Rajkumar Venkatramani; Carola Arndt

doi:10.1002/pbc.31421

Late Events Occurring After 5 Years in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group

Sara Kreimer, Wei Xue, Amira Qumseya, Timothy B. Lautz, Archana Shenoy, Susan Hiniker, Dana Casey, Rajkumar Venkatramani, Carola Arndt

Pediatric and Adolescent Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma, and 5-year overall survival exceeds 70%. With more long-term survivors, it is critical to understand the frequency of late events, including recurrence, second malignant neoplasm, and death, occurring 5 years after diagnosis, and the variables associated with these events. We report late events in patients enrolled on Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group trials from 1997 to 2013 including D9602, D9803, D9802, ARST0331, ARST0431, ARST0531, and ARST08P1. A late event occurred in 2.9% of 5-year event-free survivors supporting guidelines to limit surveillance for these events to 5 years from diagnosis.

Original language	English (US)
Article number	e31421
Journal	Pediatric Blood and Cancer
Volume	72
Issue number	1
DOIs	https://doi.org/10.1002/pbc.31421
State	Published - Jan 2025

Keywords

late events
rhabdomyosarcoma

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.31421

Cite this

@article{e46105de0a224f6ea8da8eff1d0e1bff,

title = "Late Events Occurring After 5 Years in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group",

abstract = "Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma, and 5-year overall survival exceeds 70%. With more long-term survivors, it is critical to understand the frequency of late events, including recurrence, second malignant neoplasm, and death, occurring 5 years after diagnosis, and the variables associated with these events. We report late events in patients enrolled on Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group trials from 1997 to 2013 including D9602, D9803, D9802, ARST0331, ARST0431, ARST0531, and ARST08P1. A late event occurred in 2.9% of 5-year event-free survivors supporting guidelines to limit surveillance for these events to 5 years from diagnosis.",

keywords = "late events, rhabdomyosarcoma",

author = "Sara Kreimer and Wei Xue and Amira Qumseya and Lautz, {Timothy B.} and Archana Shenoy and Susan Hiniker and Dana Casey and Rajkumar Venkatramani and Carola Arndt",

note = "Publisher Copyright: {\textcopyright} 2024 Wiley Periodicals LLC.",

year = "2025",

month = jan,

doi = "10.1002/pbc.31421",

language = "English (US)",

volume = "72",

journal = "Pediatric Blood and Cancer",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Late Events Occurring After 5 Years in Pediatric Rhabdomyosarcoma

T2 - A Report From the Children's Oncology Group

AU - Kreimer, Sara

AU - Xue, Wei

AU - Qumseya, Amira

AU - Lautz, Timothy B.

AU - Shenoy, Archana

AU - Hiniker, Susan

AU - Casey, Dana

AU - Venkatramani, Rajkumar

AU - Arndt, Carola

PY - 2025/1

Y1 - 2025/1

N2 - Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma, and 5-year overall survival exceeds 70%. With more long-term survivors, it is critical to understand the frequency of late events, including recurrence, second malignant neoplasm, and death, occurring 5 years after diagnosis, and the variables associated with these events. We report late events in patients enrolled on Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group trials from 1997 to 2013 including D9602, D9803, D9802, ARST0331, ARST0431, ARST0531, and ARST08P1. A late event occurred in 2.9% of 5-year event-free survivors supporting guidelines to limit surveillance for these events to 5 years from diagnosis.

AB - Rhabdomyosarcoma is the most common pediatric soft tissue sarcoma, and 5-year overall survival exceeds 70%. With more long-term survivors, it is critical to understand the frequency of late events, including recurrence, second malignant neoplasm, and death, occurring 5 years after diagnosis, and the variables associated with these events. We report late events in patients enrolled on Intergroup Rhabdomyosarcoma Study Group and Children's Oncology Group trials from 1997 to 2013 including D9602, D9803, D9802, ARST0331, ARST0431, ARST0531, and ARST08P1. A late event occurred in 2.9% of 5-year event-free survivors supporting guidelines to limit surveillance for these events to 5 years from diagnosis.

KW - late events

KW - rhabdomyosarcoma

UR - http://www.scopus.com/inward/record.url?scp=85208172678&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85208172678&partnerID=8YFLogxK

U2 - 10.1002/pbc.31421

DO - 10.1002/pbc.31421

M3 - Article

C2 - 39502069

AN - SCOPUS:85208172678

SN - 1545-5009

VL - 72

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

IS - 1

M1 - e31421

ER -